Outpatient Process Measures Are Focused on Underuse of Care
According to a study published in JAMA Internal Medicine, outpatient process measures need a fair balance between measures for underuse and overuse of clinical services.
At an attempt to improve quality of healthcare, a number of clinical performance measures have been developed to improve clinician and institutional performance. However, the influence of these measures on changing clinical practice on a large scale have been questioned. A primary question being raised, and which was the objective of the current study in
The authors of the study, in an attempt to understand the influence of outpatient process measures on underuse and overuse, identified all outpatient and emrgency department (ED) process measures included in major national measure programs till mid-2012. Inpatient measures were excluded from the evaluation, as were outcomes measures, settings other than outpatient or ED, and nonclinical aspects of care. A total of 521 measures of care were included in the study from across 16 measure collections.
A detailed evaluation of these measures showed that nearly 92% (477) targeted underuse while just over 6% (34) targeted overuse. Less than 3% (14) addressed misuse. Of the 16 measure collections, the authors found only 3 that included a good percentage of overuse measures (≥10%) while more than 50% did not include any overuse measures. Underuse measures, the authors write, covered all categories of clinical service, while overuse measures were restricted and addressed either diagnostic imaging or medication prescription.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- AML Survival After 3 Years in Remission Comparable With General Population
September 20th 2025
- AHA Launches New Initiative to Help Patients With Heart Failure
September 20th 2025
- CSU More Burdensome in Female Patients, Especially in Midlife
September 20th 2025
- Pirtobrutinib Shows Clinically Meaningful PFS Improvement in Frontline CLL
September 19th 2025
- Rocatinlimab AD Combo Therapy Safe, Effective Over 24 Weeks
September 19th 2025